Alnylam Pharmaceuticals
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
Phase 1
Completed
- Conditions
- Acute Intermittent Porphyria
- Interventions
- Drug: Sterile Normal Saline (0.9% NaCl)
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02452372
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
Phase 1
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: Sterile Normal Saline (0.9% NaCl)
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02352493
- Locations
- π¬π§
Richmond Pharmacology, London, United Kingdom
π¬π§Clinical Trial Site, Leeds, United Kingdom
π¬π§Covance Clinical Research Unit, Leeds, United Kingdom
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Phase 3
Completed
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)Amyloid Neuropathies, FamilialAmyloidosis, Hereditary, Transthyretin-RelatedAmyloid NeuropathiesFamilial Transthyretin Cardiac AmyloidosisAmyloidosis, Hereditary
- Interventions
- Drug: Sterile Normal Saline (0.9% NaCl)
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT02319005
- Locations
- π¬π§
Clinical Trial Site, Tooting, United Kingdom
A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Phase 1
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Sterile Normal Saline (0.9% NaCl)
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT02314442
- Locations
- π¬π§
Covance Clinical Research Unit, Leeds, United Kingdom
π¬π§Richmond Pharmacology, London, United Kingdom
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT02292186
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Completed
- Conditions
- Familial Amyloidotic Cardiomyopathy (FAC)
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 1010
- Registration Number
- NCT02252653
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Completed
- Conditions
- Acute Hepatic Porphyria
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 136
- Registration Number
- NCT02240784
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers
Phase 1
Completed
- Conditions
- Transthyretin (TTR)-Mediated Amyloidosis
- Interventions
- Drug: Sterile Normal Saline (0.9% NaCl)
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02053454
- Locations
- π¬π§
Clinical Site, London, United Kingdom
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Phase 2
Completed
- Conditions
- TTR-mediated Amyloidosis
- Interventions
- Drug: ALN-TTRSC (revusiran) for subcutaneous administration
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT01981837
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Phase 2
Completed
- Conditions
- TTR-mediated Amyloidosis
- Interventions
- Drug: ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT01961921
- Locations
- πΈπͺ
Clinical Trial Site, UmeΓ₯, Sweden